It is expected to achieve functional cure for hepatitis B and complete the first administration of RNA destabilizer

On August 16, 2021, Enanta Pharmaceuticals announced that the phase 1 clinical trial of EDP-721 has completed the first administration

Hepatitis B is a viral infection that attacks the liver and can cause acute and chronic diseases

EDP-721 is a selective inhibitor of atypical polyadenylic acid polymerases PAPD5 and PAPD7.

▲EDP-721 reduced HBsAg levels by 3 log10 IU/mL in animal models (picture source: Enanta Pharmaceuticals official website)

This two-part phase 1a/b trial will initially evaluate the safety, tolerability, and pharmacokinetics of EDP-721 in healthy volunteers as a single dose and multiple incremental oral administrations

▲The combination of nucleoside analogues, EDP-514, and EDP-721 constitutes a full oral therapy that has the potential to functionally cure hepatitis B (picture source: Enanta Pharmaceuticals official website)

Reference materials:

[1] Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer.

(The original text has been deleted)